// App-Quantinova.ai

POS0854 (2022) : BASELINE CHARACTERISTICS OF PATIENTS WITH IMPROVEMENT OR PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) DURING THE SENSCIS TRIAL

Researchers

Presenter

  • A. M. Hoffmann-Vold

Principal Investigators

  • E. Hachulla

  • A. Herrick

  • T. Moua

  • G. Riemekasten

  • M. Vonk

  • A. James

  • M. Alves

  • O. Distler

Medical Centers

  • Oslo University Hospital, Department of Pathology, Oslo, Norway

  • Université de Lille, Department of Internal Medicine and Clinical Immunology, Lille, France

  • The University of Manchester, Northern Care Alliance NHS Foundation Trust, Centre for Musculoskeletal Research, Manchester, United Kingdom

  • Mayo Clinic, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Rochester, United States of America

  • Charite University Hospital, Rheumatology and Clinical Immunology, Berlin, Germany.

  • Radboud University Medical Center, Department of Pharmacy, Nijmegen, Netherlands

  • Elderbrook Solutions GmbH, Statistics, Bietigheim-Bissingen, Germany

  • Boehringer Ingelheim International GmbH, Inflammation Medicine, Ingelheim am Rhein, Germany

  • University Hospital Zurich, University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland

Locations

  • Norway

  • France

  • United Kingdom

  • United States

  • Germany

  • Netherlands

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Mycophenolic acid

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved